SCHEDULE: Baillie Gifford Discloses Moderna Stake

Baillie Gifford & Co has updated its Schedule 13G filing, reporting beneficial ownership of 18,206,778 shares of Moderna, Inc. common stock, representing 4.6% of the class.

Summary

• Baillie Gifford & Co has filed an amended Schedule 13G, indicating their beneficial ownership of Moderna, Inc. common stock.
• The filing reports that Baillie Gifford & Co beneficially owns 18,206,778 shares of Moderna's common stock.
• This holding represents approximately 4.6% of the class of securities.
• The filing is an amendment, suggesting a previous filing was made.
• Baillie Gifford & Co is identified as an Investment Adviser.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, indicating continued institutional investment without new material information about the company's performance.

Positives

• Baillie Gifford & Co, a significant investment adviser, holds a substantial stake in Moderna, Inc.
• The reported ownership of 18,206,778 shares (4.6%) indicates confidence in Moderna's long-term prospects by a major institutional investor.

Risks

• The filing does not explicitly mention any risks associated with the investment itself, but general market risks for biotechnology companies would apply.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from Moderna, Inc. It is a disclosure of beneficial ownership by an investment adviser.

Industry Context

StockSavvy.ai notes that Baillie Gifford & Co's updated filing reflects ongoing institutional interest in the biotechnology sector, particularly in companies like Moderna that have demonstrated significant growth potential and innovation.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional investor's stake, which can be viewed positively for market confidence.
• Management: The disclosure is a routine regulatory requirement and does not directly impact day-to-day management operations.

Next Steps

• Baillie Gifford & Co will continue to hold and manage its investment in Moderna, Inc. in the ordinary course of business.

Key Dates

Keywords

Moderna, Biotechnology, Investment Adviser, Schedule 13G, Shareholder, Securities